Skip to main content
Sunday, November 15, 2026Nov 15

Drug companies forge partnerships with top schools

drug-companies-forge-partnerships-top-schools
drug-companies-forge-partnerships-top-schools
photo Matt Drever, left, scrapes bacteria from an agar plate during an antibody phage experiment as Charlie Holst watches at the Pfizer laboratory at the the University of California at San Francisco (UCSF) Mission Bay campus. Pfizer Inc., Astra Zeneca PLC and Eli Lilly and Co. are among the major international drug companies signing seven-figure, multiyear umbrella agreements with schools such as New York University, Harvard and the University of California-San Francisco. The deals cover a range of research projects and offer campus scientists access to once-proprietary experimental drug compounds owned by the corporate labs.

ST. LOUIS – In their quest for the next big drug discovery, pharmaceutical companies are increasingly teaming up with some of the nation’s top universities, recruiting campus scientists as partners and offering schools multimillion-dollar deals to work on experimental drugs in development.

Big Pharma has long sought to profit from academia’s innovations in more limited arrangements. Now the two sides are often joining forces as equals. But the drug makers’ aggressive pursuit of university research has drawn the ire of academic purists who question whether the partnerships put profits ahead of, or on equal footing with, science for science’s sake.

“What it does is to blur the boundaries between academic medical centers and investor-owned companies,” said Dr. Marcia Angell, former editor-in-chief of the New England Journal of Medicine and a prominent critic of the pharmaceutical industry’s new coziness with major campuses.

Pfizer Inc., Astra Zeneca PLC and Eli Lilly and Co. are among the major international drug companies signing agreements with schools such as New York University, Harvard and the University of California at San Francisco.

Driving the change is the expiration of patents for such lucrative name-brand drugs as Seroquel, Lipitor and Protonix, which industry observers say accounted for nearly $36 billion in U.S. sales in 2011 and 2012. More than ever, drug makers need new revenue to replace diminished profits from drugs that now have generic rivals.